Andreas Kuznik
Overview
Explore the profile of Andreas Kuznik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1010
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wu N, Kuznik A, Wang D, Moretz C, Xi A, Kumar S, et al.
Clinicoecon Outcomes Res
. 2020 Dec;
12:723-731.
PMID: 33293840
Background: Emerging trial data for treatment of COVID-19 suggest that in addition to improved clinical outcomes, these treatments reduce length of hospital stay (LOS). However, the economic value of a...
12.
Keeping S, Xu Y, Chen C, Cope S, Mojebi A, Kuznik A, et al.
Future Oncol
. 2020 Oct;
17(5):611-627.
PMID: 33052055
To estimate the comparative efficacy of cemiplimab, a programmed cell death protein 1 inhibitor, versus EGFR inhibitors, pembrolizumab and platinum-based chemotherapy in terms of overall survival (OS) and progression-free survival....
13.
Habib A, Musa B, Iliyasu G, Hamza M, Kuznik A, Chippaux J
PLoS Negl Trop Dis
. 2020 Aug;
14(8):e0008374.
PMID: 32817674
No abstract available.
14.
Silverberg J, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya U, Mastey V, et al.
Ann Allergy Asthma Immunol
. 2020 Aug;
126(1):40-45.
PMID: 32739313
Background: The real-world persistence with dupilumab therapy for atopic dermatitis (AD) is unknown. Objective: To characterize adults with AD who initiated dupilumab and evaluate persistence with dupilumab therapy. Methods: This...
15.
Mukose A, Kebede S, Muhumuza C, Makumbi F, Komakech H, Bayiga E, et al.
Biomed Res Int
. 2020 Jun;
2020:2875864.
PMID: 32550228
Background: In 2013, the World Health Organization (WHO) revised the 2012 guidelines on use of antiretroviral drugs (ARVs) for the prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV)....
16.
Moshfeghi A, Lanitis T, Kropat G, Kuznik A, Gibson A, Feng H, et al.
Ophthalmic Surg Lasers Imaging Retina
. 2020 Apr;
51(4):S6-S14.
PMID: 32348529
Background And Objective: To estimate the social cost of blindness due to wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR) in the United States...
17.
Muszbek N, Proudfoot C, Fournier M, Chen C, Kuznik A, Kiss Z, et al.
J Manag Care Spec Pharm
. 2019 Oct;
25(11):1268-1280.
PMID: 31663465
Background: Despite a substantial number of treatment options in rheumatoid arthritis (RA) following tumor necrosis factor inhibitor (TNFi) inadequate response or intolerance (TNF-IR), a lack of clarity on the optimal...
18.
Simoes E, Chirikov V, Botteman M, Kwon Y, Kuznik A
J Infect Dis
. 2019 Jun;
221(8):1256-1270.
PMID: 31165865
Background: Respiratory syncytial virus (RSV) is the primary cause of respiratory tract infections in infants; however, current burden estimates report only the short-term effects of acute infection. Methods: Infants with...
19.
Ariens L, Gadkari A, van Os-Medendorp H, Ayyagari R, Terasawa E, Kuznik A, et al.
Acta Derm Venereol
. 2019 May;
99(10):851-857.
PMID: 31099402
Dupilumab is approved for uncontrolled moderate-to-severe atopic dermatitis (AD); cyclosporine is approved for severe AD for ≤ 1 year. The efficacy/effectiveness of these treat-ments was compared indirectly. Regression models used...
20.
Muszbek N, Proudfoot C, Fournier M, Chen C, Kuznik A, Kiss Z, et al.
Adv Ther
. 2019 Apr;
36(6):1337-1357.
PMID: 31004324
Introduction: Assess the cost-effectiveness (US healthcare payer perspective) of sarilumab subcutaneous (SC) 200 mg + methotrexate versus conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or targeted DMARD + methotrexate for moderate-to-severe...